FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Proposes 6 Bulk Drug Substances for 503A List

[ Price : $8.95]

FDA releases a final rule with six bulk drug substances to be included on the Section 503A drug compounding bulks list and four su...

Attorneys Explain Antikickback Rule

[ Price : $8.95]

Two Hyman, Phelps attorneys explain provisions in a new HHS Inspector General final rule on antikickback safe harbors and civil mo...

Web Page Misleads on Tuxarin: FDA

[ Price : $8.95]

CDERs Office of Prescription Drug Promotion warns Spriaso about a Tuxarin ER Web page that gives false and misleading risk informa...

Team Wins $40,000 in Naloxone App Competition

[ Price : $8.95]

FDA associate commissioner Peter Lurie says the winner of an FDA-sponsored Naloxone App Competition was OD Help, created by Team P...

Professional E-mail Misbrands Renacidin

[ Price : $8.95]

CDERs Office of Prescription Drug Promotion warns United-Guardian about a professional e-mail that misbrands its Renacidin.

Woodcock: Business as Usual as New Administration Looms

[ Price : $8.95]

CDER director Janet Woodcock says she is not too concerned with an Administration change next month, saying that for now it is bus...

Reject Innovator Theory of Liability: WLF

[ Price : $8.95]

Washington Legal Foundation asks the California Supreme Court to reject a theory of innovator liability a lower state court used t...

FDA Names Solomon to Head CVM

[ Price : $8.95]

FDA names deputy associate commissioner for regulatory affairs Steven M. Solomon, DVM, as the new Center for Veterinary Medicine d...

Guidance on Electronic Informed Consent Q&A

[ Price : $8.95]

Federal Register Notice: FDA and HHSs Office for Human Research Protections make available a guidance entitled Use of Electronic I...

Osmotica Asks BE Test for Venlafaxine

[ Price : $8.95]

Osmotica asks FDA to require in vivo ANDA bioequivalence testing for the 225 mg strength of its venlafaxine HCl.